For instance, RNF181 can modulate signaling pathways that involve Hippo/YAP, CARD11 and ERK/MAPK-cyclin D1/CDK4, and it has been implicated in diseases like triple negative breast cancer and gastric cancer [75–79]. Here, RNF181 is linked to triple-negative breast carcinoma.